NCT03556592 - Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 13, 2018

Primary Completion Date

March 16, 2020

Study Completion Date

June 20, 2020

Conditions

Atopic Dermatitis

Interventions

DRUG

Tralokinumab

Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection.

DRUG

Caffeine

1x 100 mg tablet

DRUG

Warfarin

2x 5 mg tablets

DRUG

Omeprazole

1x 20 mg capsule

DRUG

Metoprolol

1x 100 mg tablet

DRUG

Midazolam Hydrochloride

1 mL of 2 mg/mL oral solution/syrup

Trial Locations (12)

23502

LEO Pharma Investigational Site, Norfolk

29303

LEO Pharma Investigational Site, Spartanburg

33015

LEO Pharma Investigational Site, Miami

33122

LEO Pharma Investigational Site, Doral

33144

LEO Pharma Investigational Site, Miami

72212

LEO Pharma Investigational Site, Little Rock

72758

LEO Pharma Investigational Site, Rogers

75010

LEO Pharma Investigational Site, Paris

92119

LEO Pharma Investigational Site, San Diego

02169

LEO Pharma Investigational Site, Quincy

06202

LEO Pharma Investigational Site, Nice

2333 ZC

LEO Pharma Investigational Site, Leiden